Rationale: For patients with asymptomatic high-grade carotid stenosis, clinical investigations have focused on preventing cerebral infarction, yet stenosis that reduces cerebral blood flow may independently impair cognition. Whether revascularization of a hemodynamically significant carotid stenosis can alter the course of cognitive decline has never been investigated in the context of a randomized clinical trial.
Introduction
Vascular cognitive impairment is often described as a step-wise or progressive disease resulting from accumulated ischemic injury. [1] [2] [3] [4] Cerebral hemodynamic impairment in patients with high-grade carotid artery stenosis can also impair cognition when there is low cerebral blood flow (CBF) on the side of stenosis, even if no clinically evident stroke has occurred. [5] [6] [7] Although there is suggestive evidence from case series that hemodynamic impairment affects cognition in patients with carotid occlusive disease, treatment of this condition to reverse cognitive decline has never been tested in the context of a randomized trial. The Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis -Hemodynamics (CREST-H) study is designed to address this knowledge gap.
Rationale
Preclinical data suggest that there is a direct effect of cerebral hypoperfusion on cognition from carotid occlusive disease and that it is reversible. Middle-aged rats underwent bilateral common carotid plus left subclavian artery ligation to produce ''chronic cerebrovascular insufficiency.'' This resulted in low CBF, selective hippocampal CA1 damage, and poorer performance on a water maze test. 8 Rats that were de-occluded at 1-2 weeks by releasing the carotid ligation showed CBF levels similar to intact controls, limited CA1 damage, and improved performance on the water maze test. This model was the first to suggest that a state of ''chronic ischemia'' from large vessel occlusion might reverse with restoration of flow.
In human studies, hemodynamic impairment in high-grade stenosis is associated with lower cognitive scores. An increased probability of developing cognitive deterioration has been demonstrated in patients with unilateral asymptomatic severe carotid stenosis compared to healthy controls (OR ¼ 14.66 (95% CI 7.51-28.59); p < 0.001). 9 We previously demonstrated that hemodynamic impairment among a cohort of patients with unilateral carotid artery occlusion was an independent predictor of cognitive impairment. 7 We recently showed a direct correlation between reduced blood flow in the cortex on the side of highgrade carotid artery stenosis and cortical thinning. 10 Clinically, reversal of cognitive impairment with revascularization has been demonstrated only in case series.
11,12 A recent study reported 137 patients with >70% internal carotid artery (ICA) stenosis who had transient ischemic attack within the last six months and underwent carotid endarterectomy (CEA). At baseline, these patients demonstrated cognitive impairments specific to the side of occlusion. At six months post-op, cognitive performance was improved and correlated with improvement in cerebral hemodynamics by breath holding index (adj R 2 > 0.70). 12 Finally, a meta-analysis of 16 studies found overall improvements in the modified mini-mental state exam and tests of attention/psychomotor speed and memory after carotid stenting. 13 
Study organization and funding
CREST-H is a National Institute of Neurological Disorders and Stroke (NINDS)-sponsored ancillary study to the NINDS-sponsored Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Study (CREST-2, clinicaltrials.gov NCT02089217). 14 CREST-2 is a pair of outcome-blinded, Phase 3 randomized clinical trials in patients with asymptomatic highgrade carotid artery stenosis, assessing stroke and death rates in patients assigned to CEA plus intensive medical management (IMM) versus IMM alone, and those assigned to carotid artery stenting plus IMM versus IMM alone. CREST-2 includes a neurocognitive battery, measuring cognitive status at baseline and yearly up to four years. Once a patient is enrolled and randomized into CREST-2, the patient is approached for CREST-H enrollment. Following CREST-H consent and cognitive assessment and prior to beginning any CREST-2 treatment, the patient undergoes an MRI perfusion scan to determine whether there is hemodynamic flow impairment. Those with flow impairment receive another perfusion scan at one-year follow-up.
We anticipate including approximately 75 sites from among the CREST-2 participating sites to achieve recruitment over the four-year enrollment period. 
Methods

Patient population
From the total of 2480 patients to be enrolled in the two CREST-2 trials approximately 500 will be enrolled in CREST-H. Enrollment into either the surgical or the stenting trial for CREST-2 is allowed since the International Journal of Stroke, 13 (9) comparison groups for CREST-H will be revascularization versus IMM alone, regardless of revascularization method. Inclusion and exclusion criteria are listed in Tables 1 and 2 . Although CREST-2 has no minimum education requirement and no upper age limit, patients older than 86 years at baseline or with less than eight years of education are excluded from CREST-H due to lack of adequate cognitive norms.
Primary outcome. The primary outcome is the change in cognitive score from baseline to one year. The primary assessment is an ''interaction hypothesis'' where the difference in cognitive outcome by treatment arm among those with hemodynamic impairment will be compared with the treatment difference in the group without hemodynamic impairment (see Figure 1) . This interaction will also be assessed at years 2, 3, and 4.
Secondary outcomes . 1 . Correlation between cognitive change and perfusion change. We hypothesize that improvement in cognition following revascularization among those with baseline hemodynamic impairment will correlate with improvement in cerebral perfusion. 2. Silent infarcts and increased white matter hyperintensity volume (WMHV) at one year. We hypothesize that the number of new silent infarcts and the WMHV at one year will be greater in the IMM-only group versus the revascularization group and may help explain changes in cognition. 3. Exploratory aims will assess cognitive change using alternative imaging measures -time-to-peak (TTP) delay >4 s, mean transit time, maximum perfusion change (Tmax), CBF, and cerebral blood volume. We will also measure cortical thickness in the target hemisphere versus the hemisphere supplied by the contralateral carotid artery.
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Data collection
Cognitive assessments. The CREST-2 telephone-based cognitive test battery uses well-validated measures in aural format, with certified test administrators (intertester reliability $98%). To make the CREST-2 battery more sensitive and specific to large vessel cerebral vascular disease, we added Oral Trail Making A & B, which enriches the assessment of executive function. Cognitive assessments take place after CREST-2 randomization but must take place prior to revascularization or up to and including the 44-day CREST-2 follow-up visit if the patient is randomized to IMM alone. At baseline and at each yearly test interval, a composite (mean) z-score is derived from published normative samples for each test element. 16 The change in the mean composite z-score from baseline will be calculated, adjusting for age, education, and depression. The test battery is administered identically for all CREST-2 and CREST-H enrolled patients, but the elements used to generate the composite z-score will differ in CREST-H, based on known sensitivity to hemodynamic compromise. Table 3 shows the CREST-2 and CREST-H batteries, with the domain and behavior outcome measures for each, indicating which measures will be used to determine the primary cognitive outcomes, respectively.
Image acquisition. MR images will be obtained at each performance site according to parameters established by CREST-H investigators. Field strength of 1.5 T or 3.0 T is allowable, although 3.0 T is preferred. A dynamic contrast susceptibility MR perfusion weighted image (PWI) will be used to stratify patients by hemodynamic status at baseline.
For secondary aims we will also evaluate: (1) WMHV by fluid attenuation inversion recovery (FLAIR), (2) cerebral microbleeds, defined as !2 mm hypointense lesions on gradient echo (GRE), (3) silent infarction, defined as hyperintense lesions with a dark center on FLAIR images !3 mm on one-year MRI not present on baseline FLAIR, (4) acute silent infarct defined by >1 mm hyperintense lesion on diffusion weighted imaging, and (5) cortical thickness measured by T1 high-resolution imaging. Table 4 lists the general acquisition parameters for each sequence. Specific parameters by MR scanner manufacturer and field strength are provided to sites to standardize across scanner types. Total scan time is under 30 min.
Image de-identification and blinding. To ensure that the PWI information from CREST-H does not produce bias in the parent trial, the site PIs for CREST-2 agree to remain blinded to any perfusion scan information and for PWI files not to be processed or read locally.
Image processing. PWI source images will be processed with a semi-automated system that computes quantitative perfusion maps using deconvolution of tissue and arterial signals in an expedited manner, yielding standardized data regardless of the acquisition system at each site. Hemodynamic impairment is defined as TTP > 2 s in the middle and anterior cerebral artery territories of the ipsilateral hemisphere to the carotid lesion compared with the same territory in the opposite hemisphere. We will quantify the change in the TTP volume at one year, comparing the revascularization versus the medical arm, using continuous values. Voxelbased changes in these serial perfusion values may provide greater detail about the severity, topography, and heterogeneity of the potentially ischemic field. Co-registered, voxel-based changes in serial perfusion values will also be explored with multiparametric values.
Sample size
It is anticipated that at least 20% (100/500) of patients enrolled in CREST-H will have hemodynamic impairment. Based on preliminary studies, 70 of these will have baseline cognitive impairment to À1.0 SD below age-matched norms. Such levels of cognition are consistent with a measurable decline in cognition not yet reaching criteria for frank dementia. In the flow-impairment group, we estimate a 0.6 SD treatment difference between those assigned to revascularization versus IMM alone. In contrast, we estimate that there will be no treatment difference among those with no flow impairment. There is 93% power to detect a differential treatment effect (i.e. interaction) of 0.5 SD, a clinically meaningful effect.
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Statistical analysis
Linear regression analysis will be used to estimate the magnitude of the treatment differences with regard to cognition among those with baseline flow impairment versus those without baseline flow impairment, with covariates age, baseline cognitive performance, depression, prior cerebral infarcts, WMHV, and microbleeds. The (two-tailed) significance level will be p ¼ 0.05. The primary hypothesis statistical model will be
where C 1 is the cognitive z-score at year 1, C 0 is the cognitive z-score at baseline, T is the treatment indicator variable, F is the flow impairment variable, and b i is the regression parameters to be estimated. The parameter of interest for the primary hypothesis is then b 3 that would assess if the magnitude of treatment difference in the change in cognitive score between baseline and one year is similar for those with versus those without flow impairment. Change in z-score will be correlated with the continuous measure of the hemodynamic impairment change. For analysis of incident silent infarction we will use linear regression if the number of new infarcts is large, International Journal of Stroke, 13 (9) or Poisson Regression if the number is smaller (considered less likely). The analysis of the change in WMH will use linear regression.
Summary and conclusions
This ancillary study provides an unparalleled opportunity to address an unanswered question regarding the relationship between hemodynamic impairment and cognition within the rigor of a randomized clinical trial. If we can demonstrate the ability to reverse cognitive decline with a mechanical intervention in a hemodynamically impaired subset of patients, this would re-define ''symptomatic'' carotid disease to include cognition, and further our understanding of the pathophysiology of vascular cognitive impairment.
